iX has a portfolio of products in the pipeline for pain management.
Some of these products may be developed along the FDA's Sections 505(b)(2) and 505(j) approval process. These expedited regulatory pathways have the potential to allow iX to bring its products to market faster, with lesser risk and expense.
iX's lead product in development is Wafermine™, which is the is the world's first sublingual ketamine oral wafer that contains the non-opioid drug, ketamine. Wafermine™ utilises iX's proprietary WaferiX™ sublingual technology.
BnoX™ is a sublingual buprenorphine oral wafer. BnoX™ utilises iX's proprietary WaferiX™ sublingual technology.
Wafesil™ is a sublingual oral wafer containing sildenafil citrate as the approved active ingredient for the treatment of male erectile dysfunction.
Wafernyl™ is a sublingual fentanyl oral wafer in development for breakthrough cancer pain. Wafernyl™ utilises iX's proprietary WaferiX™ sublingual technology